bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S6 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Authors: Serra-Camprubí Queralt , Verdaguer Helena , Oliveros Winona , Lupión-Garcia Núria , Llop-Guevara Alba , Molina Cristina , Vila-Casadesús Maria , Turpin Anthony , Neuzillet Cindy , Frigola Joan , Querol Jessica , Yáñez-Bartolomé Mariana , Castet Florian , Fabregat-Franco Carles , Escudero-Iriarte Carmen , Escorihuela Marta , Arenas Enrique J. , Bernadó-Morales Cristina , Haro Noemí , Giles Francis J. , Pozo Óscar J. , Miquel Josep M. , Nuciforo Paolo G. , Vivancos Ana , Melé Marta , Serra Violeta , Arribas Joaquín , Tabernero Josep , Peiró Sandra , Macarulla Teresa , Tian Tian V.
Published: April 2023

Evaluation of RAD51 scores in CCA_PDXs and CCA patients. (A) RAD51 scores of CCA_PDXs and their matched originating biopsy samples. (B) RAD51 scores evaluated in PDX85 (IDH1mut) treated as for Figure 4C.
Supplementary Data 2 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Authors: Gopal Priyanka , Yard Brian D. , Petty Aaron , Lal Jessica C. , Bera Titas K. , Hoang Trung Q. , Buhimschi Alexandru D. , Abazeed Mohamed E.
Published: April 2023

Supplementary Data 2: Alleles profiled and radiation sensitivity data
Supplementary Data 1 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Authors: Gopal Priyanka , Yard Brian D. , Petty Aaron , Lal Jessica C. , Bera Titas K. , Hoang Trung Q. , Buhimschi Alexandru D. , Abazeed Mohamed E.
Published: April 2023

Supplementary Data 1: Missense mutations in BEAS-2B cell line
Figure S1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Authors: Giraldo Nicolas A. , Drill Esther , Satravada Baby A. , Dika Imane El , Brannon A. Rose , Dermawan Josephine , Mohanty Abhinita , Ozcan Kerem , Chakravarty Debyani , Benayed Ryma , Vakiani Efsevia , Abou-Alfa Ghassan K. , Kundra Ritika , Schultz Nikolaus , Li Bob T. , Berger Michael F. , Harding James J. , Ladanyi Marc , O'Reilly Eileen M. , Jarnagin William , Vanderbilt Chad , Basturk Olca , Arcila Maria E.
Published: April 2023

Figure S1. Mutation signatures and altered canonical pathways in GBC.
Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Authors: Oh Seung Yeon , Lee You Won , Lee Eun Ji , Kim Jae Hwan , Park YoungJoon , Heo Seong Gu , Yu Mi Ra , Hong Min Hee , DaSilva John , Daly Christopher , Cho Byoung Chul , Lim Sun Min , Yun Mi Ran
Published: April 2023

Whole Exom Sequencing_Somatic Mutation
Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Authors: Vaishampayan Ulka N. , Thakur Archana , Chen Wei , Deol Abhinav , Patel Meera , Dobson Kimberlee , Dickow Brenda , Schalk Dana , Schienschang Amy , Whitaker Sarah , Polend Amanda , Fontana Joseph A. , Heath Elisabeth I. , Lum Lawrence G.
Published: April 2023

Shows Phenotype, Viability, and Cytotoxicity of the Product.
Supplementary Table S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Authors: Vaishampayan Ulka N. , Thakur Archana , Chen Wei , Deol Abhinav , Patel Meera , Dobson Kimberlee , Dickow Brenda , Schalk Dana , Schienschang Amy , Whitaker Sarah , Polend Amanda , Fontana Joseph A. , Heath Elisabeth I. , Lum Lawrence G.
Published: April 2023

Representativeness of Study Participants.
Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Authors: Oh Seung Yeon , Lee You Won , Lee Eun Ji , Kim Jae Hwan , Park YoungJoon , Heo Seong Gu , Yu Mi Ra , Hong Min Hee , DaSilva John , Daly Christopher , Cho Byoung Chul , Lim Sun Min , Yun Mi Ran
Published: April 2023

(A-B) Cells were incubated with the REGN5093-M114, IgG4 control-M114, osimertinib for 5 days, capmatinib for 3 days. Cell viability was analyzed via CellTiter-Glo. The curved graphs show the cell viability results for a single drug, and the bar-graphs show the cell viability for the combination of two drugs.
Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Authors: Oh Seung Yeon , Lee You Won , Lee Eun Ji , Kim Jae Hwan , Park YoungJoon , Heo Seong Gu , Yu Mi Ra , Hong Min Hee , DaSilva John , Daly Christopher , Cho Byoung Chul , Lim Sun Min , Yun Mi Ran
Published: April 2023

(A-B) Apoptosis level was measured after incubated with drugs for 48 hours. YU1089 and HCC827 AR cells were treated with osimertinib, capmatinib or tepotinib at a concentration of 100nM, Control Ab-M114 at 1 µg/ml or REGN5093-M114 at 1 µg/ml.
Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Authors: Oh Seung Yeon , Lee You Won , Lee Eun Ji , Kim Jae Hwan , Park YoungJoon , Heo Seong Gu , Yu Mi Ra , Hong Min Hee , DaSilva John , Daly Christopher , Cho Byoung Chul , Lim Sun Min , Yun Mi Ran
Published: April 2023

(A-D) YUO-006 and YUO-010 (Patient-derived organoids), YU-1089 and YU-1095 (Patient-derived cells) or HCC827-AR and H820 (ATCC cell lines) were seeded on a 96-well plate and incubated with the MET TKIs (tepotinib) and EGFR TKIs (osimertinib or gefitinib) for 3 days. EGFR TKIs was treated with concentration of 0nM, 30nM, 100nM. MET TKIs, tepotinib were treated with serial concentrations from 0nM to 100nM. The bar-graphs show the cell viability for the combination of two drugs, and the curved graphs show the cell viability results for a single drug.
Supplementary Figure S2 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
Authors: Wang Jun , Guo Wei , Wang Xiaofang , Tang Xiaodong , Sun Xin , Ren Tingting
Published: April 2023

Confirmation of characteristics of serum exosomes in patients with OS A. Transmission electron microscopy showing the morphology of Sr-exosomes; B. Nanoparticle tracking system revealing the size of Sr-exosomes; C. Western blot analysis for exosomes associated biomarkers.
Supplementary Data 2 from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
Authors: Fernández-Miranda Ismael , Pedrosa Lucía , Llanos Marta , Franco Fernando F. , Gómez Sagrario , Martín-Acosta Paloma , García-Arroyo Francisco R. , Gumá Josep , Horcajo Beatriz , Ballesteros Ana K. , Gálvez Laura , Martínez Natividad , Marín Miguel , Sequero Silvia , Navarro Marta , Yanguas-Casás Natalia , Calvo Virginia , Rueda-Domínguez Antonio , Provencio Mariano , Sánchez-Beato Margarita
Published: April 2023

Supplementary Data 2
Supplementary Figure S4 from Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Authors: Albanell Joan , Pérez-García José Manuel , Gil-Gil Miguel , Curigliano Giuseppe , Ruíz-Borrego Manuel , Comerma Laura , Gibert Joan , Bellet Meritxell , Bermejo Begoña , Calvo Lourdes , de la Haba Juan , Espinosa Enrique , Minisini Alessandro Marco , Quiroga Vanesa , Santaballa Bertran Ana , Mina Leonardo , Bellosillo Beatriz , Rojo Federico , Menéndez Silvia , Sampayo-Cordero Miguel , Popa Crina , Malfettone Andrea , Cortés Javier , Llombart-Cussac Antonio
Published: April 2023

(A) Longitudinal ctDNA quantification during study treatment. (B) Variations of ctDNA during study treatment. (C, D) Kaplan-Meier analyses of investigator-assessed progression-free survival according to the ctDNA detection after 2 weeks and 12 weeks of study treatment.
Supplementary Table 6 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
Authors: Mierzwa Michelle L. , Aryal Madhava , Lee Choonik , Schipper Matthew , VanTil Monica , Morales Krystal , Swiecicki Paul L. , Casper Keith A. , Malloy Kelly M. , Spector Matthew E. , Shuman Andrew G. , Chinn Steven B. , Prince Mark E.P. , Stucken Chaz L. , Rosko Andrew J. , Lawrence Theodore S. , Brenner J. Chad , Rosen Benjamin , Schonewolf Caitlin A. , Shah Jennifer , Eisbruch Avraham , Worden Francis P. , Cao Yue
Published: April 2023

Linear mixed model results for arm*time interaction EORTC QLQ30/HN35 PRO subscales.
Supplementary Figure S3 from Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Authors: Albanell Joan , Pérez-García José Manuel , Gil-Gil Miguel , Curigliano Giuseppe , Ruíz-Borrego Manuel , Comerma Laura , Gibert Joan , Bellet Meritxell , Bermejo Begoña , Calvo Lourdes , de la Haba Juan , Espinosa Enrique , Minisini Alessandro Marco , Quiroga Vanesa , Santaballa Bertran Ana , Mina Leonardo , Bellosillo Beatriz , Rojo Federico , Menéndez Silvia , Sampayo-Cordero Miguel , Popa Crina , Malfettone Andrea , Cortés Javier , Llombart-Cussac Antonio
Published: April 2023

The level of mutant and wild-type circulating DNA in baseline plasma samples by patient.
Supplementary Figure S2 from Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Authors: Albanell Joan , Pérez-García José Manuel , Gil-Gil Miguel , Curigliano Giuseppe , Ruíz-Borrego Manuel , Comerma Laura , Gibert Joan , Bellet Meritxell , Bermejo Begoña , Calvo Lourdes , de la Haba Juan , Espinosa Enrique , Minisini Alessandro Marco , Quiroga Vanesa , Santaballa Bertran Ana , Mina Leonardo , Bellosillo Beatriz , Rojo Federico , Menéndez Silvia , Sampayo-Cordero Miguel , Popa Crina , Malfettone Andrea , Cortés Javier , Llombart-Cussac Antonio
Published: April 2023

Summary of all adverse events according to NCI-CTCAE version 4.0.3.
Supplementary Figure 1 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
Authors: Mierzwa Michelle L. , Aryal Madhava , Lee Choonik , Schipper Matthew , VanTil Monica , Morales Krystal , Swiecicki Paul L. , Casper Keith A. , Malloy Kelly M. , Spector Matthew E. , Shuman Andrew G. , Chinn Steven B. , Prince Mark E.P. , Stucken Chaz L. , Rosko Andrew J. , Lawrence Theodore S. , Brenner J. Chad , Rosen Benjamin , Schonewolf Caitlin A. , Shah Jennifer , Eisbruch Avraham , Worden Francis P. , Cao Yue
Published: April 2023

KM curves of average patient p16+ and p16- LRF outcomes. Plot for estimated incidence of loco-regional failure (LRF) with the median boost volume (6.9cc) and GTV primary (54.8cc) for: p16+ OPSCC (left panel) and LAHNSCC (right panel).
Figure S5 from NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects
Authors: Belhadj Sami , Khurram Aliya , Bandlamudi Chaitanya , Palou-Márquez Guillermo , Ravichandran Vignesh , Steinsnyder Zoe , Wildman Temima , Catchings Amanda , Kemel Yelena , Mukherjee Semanti , Fesko Benjamin , Arora Kanika , Mehine Miika , Dandiker Sita , Izhar Aalin , Petrini John , Domchek Susan , Nathanson Katherine L. , Brower Jamie , Couch Fergus , Stadler Zsofia , Robson Mark , Walsh Michael , Vijai Joseph , Berger Michael , Supek Fran , Karam Rachid , Topka Sabine , Offit Kenneth
Published: April 2023

Supplementary Figure S5. Cancer types diagnosed in the carriers of germline NBN variants found to be enriched in cases compared to controls. Information about somatic loss of heterozygosity (LOH) is included. NSCLC: NonSmall Cell Lung Cancer, CUP, Cancer of Unknown Primary.
Supplementary Data Legend LS1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Authors: Ma Yuanqing , Joyce Allison , Brandenburg Olivia , Saatchi Faeze , Stevens Christina , Toffessi Tcheuyap Vanina , Christie Alana , Do Quyen N. , Fatunde Oluwatomilade , Macchiaroli Alyssa , Wong So C. , Woolford Layton , Yousuf Qurratulain , Miyata Jeffrey , Carrillo Deyssy , Onabolu Oreoluwa , McKenzie Tiffani , Mishra Akhilesh , Hardy Tanner , He Wei , Li Daniel , Ivanishev Alexander , Zhang Qing , Pedrosa Ivan , Kapur Payal , Schluep Thomas , Kanner Steven B. , Hamilton James , Brugarolas James
Published: April 2023

Supp data legend
Supplementary Table 2 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
Authors: Haertle Larissa , Barrio Santiago , Munawar Umair , Han Seungbin , Zhou Xiang , Simicek Michal , Vogt Cornelia , Truger Marietta , Fernandez Rafael Alonso , Steinhardt Maximilian , Weingart Julia , Snaurova Renata , Nerreter Silvia , Teufel Eva , Garitano-Trojaola Andoni , Da Viá Matteo , Ruiz-Heredia Yanira , Rosenwald Andreas , Bolli Niccolò , Hajek Roman , Raab Peter , Raab Marc S. , Weinhold Niels , Haferlach Claudia , Haaf Thomas , Martinez-Lopez Joaquin , Einsele Hermann , Rasche Leo , Kortüm K. Martin
Published: April 2023

Primers used for DBS.
Supplementary Figure 1 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
Authors: Haertle Larissa , Barrio Santiago , Munawar Umair , Han Seungbin , Zhou Xiang , Simicek Michal , Vogt Cornelia , Truger Marietta , Fernandez Rafael Alonso , Steinhardt Maximilian , Weingart Julia , Snaurova Renata , Nerreter Silvia , Teufel Eva , Garitano-Trojaola Andoni , Da Viá Matteo , Ruiz-Heredia Yanira , Rosenwald Andreas , Bolli Niccolò , Hajek Roman , Raab Peter , Raab Marc S. , Weinhold Niels , Haferlach Claudia , Haaf Thomas , Martinez-Lopez Joaquin , Einsele Hermann , Rasche Leo , Kortüm K. Martin
Published: April 2023

Patient-derived mutations impair PI response to Carfilzomib and Ixazomib.
Cytotoxicity assay and IC50 values of RPMI-8226 MM cell lines harboring two different stably expressed patient-derived mutations in proteasome subunits. The mutants were more resistant to the proteasome inhibitors Carfilzomib and Ixazomib compared to the controls (*) harboring lentivirally-encoded WT sequence of PSMC6/PSMD1. Shown are the means and standard deviations of three independent experiments (biological replicates) and three technical replicates in each experiment. The PSMC6 and PSMD1 expression levels were equivalent for the mutants and the controls.
Supplementary Table from Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
Authors: van IJzendoorn David G.P. , Matusiak Magdalena , Charville Gregory W. , Spierenburg Geert , Varma Sushama , Colburg Deana R.C. , van de Sande Michiel A.J. , van Langevelde Kirsten , Mohler David G. , Ganjoo Kristen N. , Bui Nam Q. , Avedian Raffi S. , Bovée Judith V.M.G. , Steffner Robert , West Robert B. , van de Rijn Matt
Published: April 2023

Supplementary Table from Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
Supplementary Figure S7 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Authors: Mishra Akhilesh , Kumar Dhiraj , Gupta Kuldeep , Lofland Gabriela , Sharma Ajay Kumar , Banka Dhanush S. , Hobbs Robert F. , Dannals Robert F. , Rowe Steven P. , Gabrielson Edward , Nimmagadda Sridhar
Published: April 2023

Ex vivo biodistribution of [68Ga]Ga-DK223 in mice bearing BFTC909 xenografts and treated with aPD-L1 antibodies for 120 h.
Supplementary Figure S5 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Authors: Mishra Akhilesh , Kumar Dhiraj , Gupta Kuldeep , Lofland Gabriela , Sharma Ajay Kumar , Banka Dhanush S. , Hobbs Robert F. , Dannals Robert F. , Rowe Steven P. , Gabrielson Edward , Nimmagadda Sridhar
Published: April 2023

Evaluation of [68Ga]Ga-DK223 ability to detect inducible PD-L1.
Supplementary Table S1 from Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Authors: O'Connell Casey L. , Baer Maria R. , Ørskov Andreas Due , Saini Sunil Kumar , Duong Vu H. , Kropf Patricia , Hansen Jakob Werner , Tsao-Wei Denice , Jang Hyo Sik , Emadi Ashkan , Holmberg-Thyden Staffan , Cowland Jack , Brinker Brett T. , Horwood Kristin , Burgos Ryan , Hostetter Galen , Youngblood Benjamin A. , Hadrup Sine Reker , Issa Jean-Pierre , Jones Peter , Baylin Stephen B. , Siddiqi Imran , Grønbaek Kirsten
Published: April 2023

Specific genes sequenced in bone marrow mononuclear cells.
Supplementary Figure S3 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Authors: Mishra Akhilesh , Kumar Dhiraj , Gupta Kuldeep , Lofland Gabriela , Sharma Ajay Kumar , Banka Dhanush S. , Hobbs Robert F. , Dannals Robert F. , Rowe Steven P. , Gabrielson Edward , Nimmagadda Sridhar
Published: April 2023

A, Comparison of hPD-L1 surface expression in different cancer cell lines with respective isotype.
Supplementary Figure S4 from Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Authors: O'Connell Casey L. , Baer Maria R. , Ørskov Andreas Due , Saini Sunil Kumar , Duong Vu H. , Kropf Patricia , Hansen Jakob Werner , Tsao-Wei Denice , Jang Hyo Sik , Emadi Ashkan , Holmberg-Thyden Staffan , Cowland Jack , Brinker Brett T. , Horwood Kristin , Burgos Ryan , Hostetter Galen , Youngblood Benjamin A. , Hadrup Sine Reker , Issa Jean-Pierre , Jones Peter , Baylin Stephen B. , Siddiqi Imran , Grønbaek Kirsten
Published: April 2023

A. Gating strategy applied for flow cytometry analysis of NK cell panel. Phenotype of NK cell (CD56dim CD16+ ) activation was quantified using expression of cell surface markers CD69, CD107a, CD45RA, and CD45RO based on the indicated gates. B. NK cell frequency before and after the treatment analyzed in PBMCs from 18 patient samples and grouped according long-and short-survivors. C. Frequency of NK cells expressing cell surface activation markers CD69, CD107a, and CD45RA and CD45RO measured in short-and long-survival groups before and after the treatment.
Supplementary Table S5 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
Authors: Zhou Yan , Yang Qingcheng , Dong Yang , Ji Tong , Zhang Bing , Yang Cheng , Zheng Shuier , Tang Lina , Zhou Chenliang , Qian Guowei , Huang Yujing , Yu Wenxi , Li Hongtao , Wang Yonggang , He Aina , Shen Zan , Bao Qiyuan , Hua Yingqi , Bai Hongyu , Zhao Jiayi , Li Xiaoyi , Dai Xiangrong , Zhang Jianjun , Hu Haiyan , Yao Yang
Published: April 2023

Representativeness of study participants
Supplementary Table S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
Authors: Zhou Yan , Yang Qingcheng , Dong Yang , Ji Tong , Zhang Bing , Yang Cheng , Zheng Shuier , Tang Lina , Zhou Chenliang , Qian Guowei , Huang Yujing , Yu Wenxi , Li Hongtao , Wang Yonggang , He Aina , Shen Zan , Bao Qiyuan , Hua Yingqi , Bai Hongyu , Zhao Jiayi , Li Xiaoyi , Dai Xiangrong , Zhang Jianjun , Hu Haiyan , Yao Yang
Published: April 2023

Summary of Exposure to ZKAB001, All Treated Patient Population
Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
Authors: Zhou Yan , Yang Qingcheng , Dong Yang , Ji Tong , Zhang Bing , Yang Cheng , Zheng Shuier , Tang Lina , Zhou Chenliang , Qian Guowei , Huang Yujing , Yu Wenxi , Li Hongtao , Wang Yonggang , He Aina , Shen Zan , Bao Qiyuan , Hua Yingqi , Bai Hongyu , Zhao Jiayi , Li Xiaoyi , Dai Xiangrong , Zhang Jianjun , Hu Haiyan , Yao Yang
Published: April 2023

Kaplan-Meier curves for Event-free Survival (EFS) in each dose group
Supplementary Figure S6 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Authors: Janssens Katleen , Vanhoutte Greetje , Lybaert Willem , Demey Wim , Decaestecker Jochen , Hendrickx Koen , Rezaei Kalantari Hassan , Zwaenepoel Karen , Pauwels Patrick , Fransen Erik , Op de Beeck Ken , Van Camp Guy , Rolfo Christian , Peeters Marc
Published: April 2023

Follow-up of patients during treatment using methylated ctDNA.
Supplementary Figure 2 from Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
Authors: Rugo Hope S. , Raskina Kira , Schrock Alexa B. , Madison Russell W. , Graf Ryon P. , Sokol Ethan S. , Sivakumar Smruthy , Lee Jessica K. , Fisher Virginia , Oxnard Geoffrey R. , Tukachinsky Hanna
Published: April 2023

Supplementary Figure 2. CONSORT diagrams for the cohorts with clinicogenomic data
Supplementary Table S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Authors: Visvanathan Kala , Cope Leslie , Fackler Mary Jo , Considine Michael , Sokoll Lori , Carey Lisa A. , Forero-Torres Andres , Ingle James N. , Lin Nancy U. , Nanda Rita , Storniolo Anna Maria , Tulac Suzana , Venkatesan Neesha , Wu Natalie C. , Marla Sudhakar , Campbell Scott , Bates Michael , Umbricht Christopher B. , Wolff Antonio C. , Sukumar Saraswati
Published: April 2023

Association between week8 CM and change in CM and disease status at first restaging.
Supplementary Table S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Authors: Visvanathan Kala , Cope Leslie , Fackler Mary Jo , Considine Michael , Sokoll Lori , Carey Lisa A. , Forero-Torres Andres , Ingle James N. , Lin Nancy U. , Nanda Rita , Storniolo Anna Maria , Tulac Suzana , Venkatesan Neesha , Wu Natalie C. , Marla Sudhakar , Campbell Scott , Bates Michael , Umbricht Christopher B. , Wolff Antonio C. , Sukumar Saraswati
Published: April 2023

Association between week 4 CM and PFS and OS
Supplementary Information S1 from A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
Authors: Yap Timothy A. , LoRusso Patricia M. , Wong Deborah J. , Hu-Lieskovan Siwen , Papadopoulos Kyriakos P. , Holz Josefin-Beate , Grabowska Urszula , Gradinaru Cristian , Leung Kin-Mei , Marshall Sylwia , Reader Claire S. , Russell Roslin , Sainson Richard C.A. , Seal Claire J. , Shepherd Christopher J. , Germaschewski Fiona , Gliddon Daniel , Stern Omer , Young Lesley , Brewis Neil , Kayitalire Louis , Morrow Michelle
Published: April 2023

Supplementary information
Supplemental Figure 1 from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells
Authors: Rotolo Ramona , Leuci Valeria , Donini Chiara , Galvagno Federica , Massa Annamaria , De Santis Maria Chiara , Peirone Serena , Medico Giovanni , Sanlorenzo Martina , Vujic Igor , Gammaitoni Loretta , Basiricò Marco , Righi Luisella , Riganti Chiara , Salaroglio Iris Chiara , Napoli Francesca , Tabbò Fabrizio , Mariniello Annapaola , Vigna Elisa , Modica Chiara , D’Ambrosio Lorenzo , Grignani Giovanni , Taulli Riccardo , Hirsch Emilio , Cereda Matteo , Aglietta Massimo , Scagliotti Giorgio Vittorio , Novello Silvia , Bironzo Paolo , Sangiolo Dario
Published: April 2023

Double positive OCT3/4-PD1 subsets in the bulk NSCLC cells after cisplatin treatment.
OCT3/4 expression preferentially co-localized on PD-1+ NSCLC cells as compared with the PD-1- counterpart (14% vs 0.1%). Representative flow cytometry histograms of OCT3/4 expression are reported in figure.
Table S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Authors: Chen Evan C. , Gandler Helen , Tošić Isidora , Fell Geoffrey G. , Fiore Ashlee , Pozdnyakova Olga , DeAngelo Daniel J. , Galinsky Ilene , Luskin Marlise R. , Wadleigh Martha , Winer Eric S. , Leonard Rebecca , O'Day Kelsey , de Jonge Adrienne , Neuberg Donna , Look A. Thomas , Stone Richard M. , Frank David A. , Garcia Jacqueline S.
Published: April 2023

Representativeness of Study Participants
Supplementary Figure S5 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations
Authors: Sivakumar Smruthy , Jin Dexter X. , Rathod Ruchita , Ross Jeffrey , Cantley Lewis C. , Scaltriti Maurizio , Chen Jessica W. , Hutchinson Katherine E. , Wilson Timothy R. , Sokol Ethan S. , Vasan Neil
Published: April 2023

Comparison of co-alteration prevalence in single- and multi-PIK3CA mutated tumors.
Supplementary Figure S1 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations
Authors: Sivakumar Smruthy , Jin Dexter X. , Rathod Ruchita , Ross Jeffrey , Cantley Lewis C. , Scaltriti Maurizio , Chen Jessica W. , Hutchinson Katherine E. , Wilson Timothy R. , Sokol Ethan S. , Vasan Neil
Published: April 2023

Read support for double-PIK3CA mutation pairs in the determination of cis/trans status.
Supplementary Table S6 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Authors: Cheema Amrita K. , Li Yaoxiang , Ventimiglia Mary , Kowalczyk Keith , Hankins Ryan , Bandi Gaurav , Janowski Einsley-Marie , Grindrod Scott , Villagra Alejandro , Dritschilo Anatoly
Published: April 2023

Linear Mixed Effect Models analysis of proteomics data combining all time points post-RT.
Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Authors: Doe-Tetteh Seyram A. , Camp Sabrina Y. , Reales Dalicia , Crowdis Jett , Noronha Anne Marie , Wolff Bernadette , Alano Tina , Galle Jesse , Selcuklu S. Duygu , Viale Agnes , Socci Nicholas D. , Liu Ying L. , Tew William P. , Aghajanian Carol , Ladanyi Marc , He Meng Xiao , AlDubayan Saud H. , Mazor Roei David , Shpilberg Ofer , Hershkovitz-Rokah Oshrat , Riancho Jose A. , Hernandez Jose L. , Gonzalez-Vela M. Carmen , Buthorn Justin J. , Wilson Manda , Webber Amy E. , Yabe Mariko , Petrova-Drus Kseniya , Rosenblum Marc , Durham Benjamin H. , Abdel-Wahab Omar , Berger Michael F. , Donoghue Mark T.A. , Kung Andrew L. , Glade Bender Julia , Shukla Neerav N. , Funt Samuel A. , Dogan Ahmet , Soslow Robert A. , Al-Ahmadie Hikmat , Feldman Darren R. , Van Allen Eliezer M. , Diamond Eli L. , Solit David B.
Published: April 2023

Patient demographic data for the female patients in the Extragonadal GCT cohort (both Make-an-IMPACT and internal MSK patients, n=16)
Supplementary Table S1 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Authors: Cheema Amrita K. , Li Yaoxiang , Ventimiglia Mary , Kowalczyk Keith , Hankins Ryan , Bandi Gaurav , Janowski Einsley-Marie , Grindrod Scott , Villagra Alejandro , Dritschilo Anatoly
Published: April 2023

Overall and sub-cohort based longitudinal (24 hours to 24 months) test statistics for proteomics data set comparing each time post-RT to baseline for the prostate cancer cohort.
Supplementary Figure S1 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Authors: Cheema Amrita K. , Li Yaoxiang , Ventimiglia Mary , Kowalczyk Keith , Hankins Ryan , Bandi Gaurav , Janowski Einsley-Marie , Grindrod Scott , Villagra Alejandro , Dritschilo Anatoly
Published: April 2023

Volcano plot showing significant dysregulation of plasma metabolites at 24 hours (Panel A), one month (Panel B), 3 months (Panel C) and six months (Panel D) as compared to baseline (pre-RT).
Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Authors: Owen Dwight H. , Benner Brooke , Wei Lai , Sukrithan Vineeth , Goyal Ashima , Zhou Ye , Pilcher Carly , Suffren Sheryl-Ann , Christenson Gwen , Curtis Nancy , Jukich Megan , Schwarz Emily , Savardekar Himanshu , Norman Ruthann , Ferguson Sarah , Kleiber Barbara , Wesolowski Robert , Carson William E. , Otterson Gregory A. , Verschraegen Claire F. , Shah Manisha H. , Konda Bhavana
Published: April 2023

Water plot of best response in lung NEN.
Figure S5 from HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
Authors: Pietrantonio Filippo , Manca Paolo , Bellomo Sara Erika , Corso Simona , Raimondi Alessandra , Berrino Enrico , Morano Federica , Migliore Cristina , Niger Monica , Castagnoli Lorenzo , Pupa Serenella Maria , Marchiò Caterina , Di Bartolomeo Maria , Restuccia Eleonora , Lambertini Chiara , Tabernero Josep , Giordano Silvia
Published: April 2023

Forest plot depicting subgroup analyses for the efficacy of trastuzumab plus pertuzumab over trastuzumab plus placebo in terms of PFS (A), OS (B) and ORR (C) according to HER2 CNV quartiles.
Figure S4 from HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
Authors: Pietrantonio Filippo , Manca Paolo , Bellomo Sara Erika , Corso Simona , Raimondi Alessandra , Berrino Enrico , Morano Federica , Migliore Cristina , Niger Monica , Castagnoli Lorenzo , Pupa Serenella Maria , Marchiò Caterina , Di Bartolomeo Maria , Restuccia Eleonora , Lambertini Chiara , Tabernero Josep , Giordano Silvia
Published: April 2023

Forest plot depicting subgroup analyses for the efficacy of trastuzumab plus pertuzumab over trastuzumab plus placebo in terms of PFS (A), OS (B) and ORR (C) according to HER2 CNV (high vs low), HER2 IHC (3+ vs 2+) and AMNESIA status (positive vs negative).
Figure S3 from HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
Authors: Pietrantonio Filippo , Manca Paolo , Bellomo Sara Erika , Corso Simona , Raimondi Alessandra , Berrino Enrico , Morano Federica , Migliore Cristina , Niger Monica , Castagnoli Lorenzo , Pupa Serenella Maria , Marchiò Caterina , Di Bartolomeo Maria , Restuccia Eleonora , Lambertini Chiara , Tabernero Josep , Giordano Silvia
Published: April 2023

Correlation between HER2 CNV and chance of experiencing death in the two separate HER2 IHC subgroups (2+ versus 3+).
Figure S1 from HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
Authors: Pietrantonio Filippo , Manca Paolo , Bellomo Sara Erika , Corso Simona , Raimondi Alessandra , Berrino Enrico , Morano Federica , Migliore Cristina , Niger Monica , Castagnoli Lorenzo , Pupa Serenella Maria , Marchiò Caterina , Di Bartolomeo Maria , Restuccia Eleonora , Lambertini Chiara , Tabernero Josep , Giordano Silvia
Published: April 2023

Patients flow.
Supplementary Figure 8 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
Authors: Mondello Patrizia , Paludo Jonas , Novak Joseph P. , Wenzl Kerstin , Yang Zhi-Zhang , Jalali Shahrzad , Krull Jordan E. , Braggio Esteban , Dasari Surendra , Manske Michelle K. , Abeykoon Jithma A. , Sarangi Vivekananda , Kapoor Prashant , Paulus Aneel , Reeder Craig B. , Ailawadhi Sikander , Chanan-Khan Asher A. , Kyle Robert A. , Gertz Morie A. , Novak Anne J. , Ansell Stephen M.
Published: April 2023

Supplementary Figure 8 Boxplots showing the expression of CD69 (A), BTLA (B), and CD25+CTLA-4+ (C) in CD4+ T cells.
Figure S4 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
Authors: Von Roemeling Christina A. , Doonan Bently P. , Klippel Kelena , Schultz Daniel , Hoang-Minh Lan , Trivedi Vrunda , Li Chenglong , Russell Rylynn A. , Kanumuri Raju S. , Sharma Abhisheak , Tun Han W. , Mitchell Duane A.
Published: April 2023

Supplemental Figure 4. CA-4948 viability assessment in A20 and B16F10 cancer cells.
Supplementary Figure 2 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
Authors: Mondello Patrizia , Paludo Jonas , Novak Joseph P. , Wenzl Kerstin , Yang Zhi-Zhang , Jalali Shahrzad , Krull Jordan E. , Braggio Esteban , Dasari Surendra , Manske Michelle K. , Abeykoon Jithma A. , Sarangi Vivekananda , Kapoor Prashant , Paulus Aneel , Reeder Craig B. , Ailawadhi Sikander , Chanan-Khan Asher A. , Kyle Robert A. , Gertz Morie A. , Novak Anne J. , Ansell Stephen M.
Published: April 2023

Supplemental Fig. 2. Gene expression of non-tumor cells by cluster.
Supplementary Table 1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Authors: Davis Andrew A. , Luo Jingqin , Zheng Tiantian , Dai Chao , Dong Xiaoxi , Tan Lu , Suresh Rama , Ademuyiwa Foluso O. , Rigden Caron , Rearden Timothy P. , Clifton Katherine , Weilbaecher Katherine , Frith Ashley , Tandra Pavan K. , Summa Tracy , Haas Brittney , Thomas Shana , Hernandez-Aya Leonel F. , Peterson Lindsay L. , Wang Xiaohong , Luo Shujun J. , Zhou Kemin , Du Pan , Jia Shidong , King Bonnie L. , Krishnamurthy Jairam , Ma Cynthia X.
Published: April 2023

PredicineATLAS gene panel.
Supplementary Table S8 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Authors: Elía Andrés , Saldain Leo , Vanzulli Silvia I. , Helguero Luisa A. , Lamb Caroline A. , Fabris Victoria , Pataccini Gabriela , Martínez-Vazquez Paula , Burruchaga Javier , Caillet-Bois Ines , Spengler Eunice , Acosta Haab Gabriela , Liguori Marcos , Castets Alejandra , Lovisi Silvia , Abascal María F. , Novaro Virginia , Sánchez Jana , Muñoz Javier , Belizán José M. , Abba Martín C. , Gass Hugo , Rojas Paola , Lanari Claudia
Published: April 2023

Proteomics: Enrichment analysis from heatmap
Supplementary Table S1 from Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study
Authors: Bo Zhiyuan , Chen Bo , Zhao Zhengxiao , He Qikuan , Mao Yicheng , Yang Yunjun , Yao Fei , Yang Yi , Chen Ziyan , Yang Jinhuan , Yu Haitao , Ma Jun , Wu Lijun , Chen Kaiyu , Wang Luhui , Wang Mingxun , Shi Zhehao , Yao Xinfei , Dong Yulong , Shi Xintong , Shan Yunfeng , Yu Zhengping , Wang Yi , Chen Gang
Published: April 2023

The STARD/TRIPOD statement checklists.
Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Authors: Elía Andrés , Saldain Leo , Vanzulli Silvia I. , Helguero Luisa A. , Lamb Caroline A. , Fabris Victoria , Pataccini Gabriela , Martínez-Vazquez Paula , Burruchaga Javier , Caillet-Bois Ines , Spengler Eunice , Acosta Haab Gabriela , Liguori Marcos , Castets Alejandra , Lovisi Silvia , Abascal María F. , Novaro Virginia , Sánchez Jana , Muñoz Javier , Belizán José M. , Abba Martín C. , Gass Hugo , Rojas Paola , Lanari Claudia
Published: April 2023

Proteomics: DE and Reactome of Cyt proteins
Supplementary Figure S4 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Authors: Kurata Keiji , Samur Mehmet K. , Liow Priscilla , Wen Kenneth , Yamamoto Leona , Liu Jiye , Morelli Eugenio , Gulla Annamaria , Tai Yu-Tzu , Qi Jun , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

BRD9 occupies promoter regions of target gene.
Supplementary Figure S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Authors: Elía Andrés , Saldain Leo , Vanzulli Silvia I. , Helguero Luisa A. , Lamb Caroline A. , Fabris Victoria , Pataccini Gabriela , Martínez-Vazquez Paula , Burruchaga Javier , Caillet-Bois Ines , Spengler Eunice , Acosta Haab Gabriela , Liguori Marcos , Castets Alejandra , Lovisi Silvia , Abascal María F. , Novaro Virginia , Sánchez Jana , Muñoz Javier , Belizán José M. , Abba Martín C. , Gass Hugo , Rojas Paola , Lanari Claudia
Published: April 2023

Mifepristone plasma levels and mifepristone-related side effects. A, Plasma levels of mifepristone 7 or 14 days after mifepristone treatment. The data from 9-10 patients are shown. Data were analyzed with ANOVA for matched samples (Friedman test). B, Clinical adverse effects grade 1 recorded in mifepristone (MFP)-treated patients. C, Laboratory values. Patients M049, M095 and M140 were treated for diabetes. Patients M009, M019, M023, M042, M049, M062, M070, M077, M090, M095, M105 and M140 were treated for hypertension and patients M009, M019 and M124 were treated for hypothyroidism. Dotted areas represent normal levels. Patients under mifepristone treatment did not interrupt standard medicine care.
Supplementary Figure S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Authors: Kurata Keiji , Samur Mehmet K. , Liow Priscilla , Wen Kenneth , Yamamoto Leona , Liu Jiye , Morelli Eugenio , Gulla Annamaria , Tai Yu-Tzu , Qi Jun , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

BRD9 depletion downregulates expression of ribosome biogenesis genes.
Supplementary Figure S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Authors: Kurata Keiji , Samur Mehmet K. , Liow Priscilla , Wen Kenneth , Yamamoto Leona , Liu Jiye , Morelli Eugenio , Gulla Annamaria , Tai Yu-Tzu , Qi Jun , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

Clinical impact and biological significance of BRD9 in multiple myeloma (MM) in vitro and in vivo.
Supplementary Data S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Authors: Kurata Keiji , Samur Mehmet K. , Liow Priscilla , Wen Kenneth , Yamamoto Leona , Liu Jiye , Morelli Eugenio , Gulla Annamaria , Tai Yu-Tzu , Qi Jun , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

DifferentialExpression_RNAseq
Supplementary Figure S1 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Authors: Elía Andrés , Saldain Leo , Vanzulli Silvia I. , Helguero Luisa A. , Lamb Caroline A. , Fabris Victoria , Pataccini Gabriela , Martínez-Vazquez Paula , Burruchaga Javier , Caillet-Bois Ines , Spengler Eunice , Acosta Haab Gabriela , Liguori Marcos , Castets Alejandra , Lovisi Silvia , Abascal María F. , Novaro Virginia , Sánchez Jana , Muñoz Javier , Belizán José M. , Abba Martín C. , Gass Hugo , Rojas Paola , Lanari Claudia
Published: April 2023

A, Prevailing PR isoforms before and after mifepristone treatment and their prevailing nuclear (Nuc) or cytosolic (Cyt) localization in western blot studies. *: Prevailing PR isoforms in Western blot studies; #: Distribution of PR in the Nuc or Cyt compartments; CNB: Core needle biopsy, S: Surgical sample. In grey font: Mifepristone unresponsive tumors by Ki67 criteria. B, Representative western blots of CNB and surgical samples from all patients. The upper band is PRB and the lower band PRA, as labeled in the first set.
Supplementary Figure S4 from Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer
Authors: Leto Simonetta M. , Ferri Martina , Sassi Francesco , Zanella Eugenia R. , Cottino Francesca , Vurchio Valentina , Catalano Irene , Ferrero Alessandro , Zingaretti Caterina C. , Marchiò Caterina , Grassi Elena , Trusolino Livio , Bertotti Andrea
Published: April 2023

EGFR inhibition does not induce BIM upregulation in cetuximab-resistant PDXOs.
Supplementary Figures S1-S9 from Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Authors: Aggarwal Charu , Saba Nabil F. , Algazi Alain , Sukari Ammar , Seiwert Tanguy Y. , Haigentz Missak , Porosnicu Mercedes , Bonomi Marcelo , Boyer Jean , Esser Mark T. , Cheng Lily I. , Agrawal Sonia , Jennings Emily C. , Durham Nicholas M. , Fraser Karl , Lissa Delphine , Gong Maozhen , Ceaicovscaia Natalia , Gascó Hernández Amaya , Kumar Rakesh
Published: April 2023

Supplementary Figure S1. Patient disposition.
Supplementary Figure S2. Association of PD-L1 expression and HPV status with best antitumor response.
Supplementary Figure S3. Kaplan-Meier distribution curves for (A) PFS and (B) OS in the as-treated population according to line of treatment and platinum-refractory status, including estimates of medians.
Supplementary Figure S4. Peripheral HPV-18-specific T-cells on IFNγ ELISpot assay of PMBCs.
Supplementary Figure S5. Peripheral HPV-16 (A, C) E6-specific and (B, D) E7-specific T-cell responses on IFNγ ELISpot assay of PMBCs.
Supplementary Figure S6. Peripheral HPV-18 (A, C) E6-specific and (B, D) E7-specific T-cell responses on IFNγ ELISpot assay of PMBCs.
Supplementary Figure S7. Baseline peripheral (A) HPV-16-specific and HPV-16 (B) E6-specific and (C) E7-specific T-cell counts on IFNγ ELISpot assay of PMBCs according to best response to treatment.
Supplementary Figure S8. Baseline peripheral (A) HPV-18-specific and HPV-18 (B) E6-specific and (C) E7-specific T-cell counts on IFNγ ELISpot assay of PMBCs according to best response to treatment.
Supplementary Figure S9. (A) HPV-16-specific and (B) HPV-18-specific T-cell count measured by IFNγ ELISpot assay of PMBCs over time per individual patient (n = 34), color-coded by best response, plotted on a log10 y-axis.
Supplementary Table S3: Clinical trials of A2AR inhibitors from ENPP1 Immunobiology as a Therapeutic Target
Authors: Ruiz-Fernández de Córdoba Borja , Martínez-Monge Rafael , Lecanda Fernando
Published: April 2023

Clinical trials of A2AR inhibitors
Supplemental Figure 2 from Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit
Authors: Mascarella Marco A. , Olonisakin Tolani F. , Rumde Purva , Vendra Varun , Nance Melonie A. , Kim Seungwon , Kubik Mark W. , Sridharan Shaum S. , Ferris Robert L. , Fenton Moon J. , Clayburgh Daniel R. , Ohr James P. , Joyce Sonali C. , Sen Malabika , Herman James G. , Grandis Jennifer R. , Zandberg Dan P. , Duvvuri Umamaheswar
Published: April 2023

Detection of methylated DNA in plasma of HNSCC patients
Supplementary Table S1. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
Authors: Morgan Robert D. , Clamp Andrew R. , White Daniel J. , Price Marcus , Burghel George J. , Ryder W. David J. , Mahmood Reem D. , Murphy Alexander D. , Hasan Jurjees , Mitchell Claire L. , Salih Zena , Wheeler Chelsey , Buckley Emma , Truelove Joanna , King Georgia , Ainaoui Yasmina , Bhaskar Sanjeev S. , Shaw Joseph , Evans D. Gareth R. , Kilerci Bedirhan , Pearce Simon P. , Brady Gerard , Dive Caroline , O'Connor James P.B. , Wallace Andrew J. , Rothwell Dominic G. , Edmondson Richard J. , Jayson Gordon C.
Published: April 2023

Serious adverse events.
Supplementary Figure S4. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
Authors: Morgan Robert D. , Clamp Andrew R. , White Daniel J. , Price Marcus , Burghel George J. , Ryder W. David J. , Mahmood Reem D. , Murphy Alexander D. , Hasan Jurjees , Mitchell Claire L. , Salih Zena , Wheeler Chelsey , Buckley Emma , Truelove Joanna , King Georgia , Ainaoui Yasmina , Bhaskar Sanjeev S. , Shaw Joseph , Evans D. Gareth R. , Kilerci Bedirhan , Pearce Simon P. , Brady Gerard , Dive Caroline , O'Connor James P.B. , Wallace Andrew J. , Rothwell Dominic G. , Edmondson Richard J. , Jayson Gordon C.
Published: April 2023

Cell-free circulating DNA copy-number profiles.
Supplementary Table S4 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Authors: Lee Hyun-Sung , Jang Hee-Jin , Ramineni Maheshwari , Wang Daniel Y. , Ramos Daniela , Choi Jong Min , Splawn Taylor , Espinoza Monica , Almarez Michelle , Hosey Leandria , Jo Eunji , Hilsenbeck Susan , Amos Christopher I. , Ripley R. Taylor , Burt Bryan M.
Published: April 2023

Supplementary Table 4. Univariable analysis of variables associated with pathologic response and overall survival following neoadjuvant ICB (N=17).
Supplementary Figure S1. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
Authors: Morgan Robert D. , Clamp Andrew R. , White Daniel J. , Price Marcus , Burghel George J. , Ryder W. David J. , Mahmood Reem D. , Murphy Alexander D. , Hasan Jurjees , Mitchell Claire L. , Salih Zena , Wheeler Chelsey , Buckley Emma , Truelove Joanna , King Georgia , Ainaoui Yasmina , Bhaskar Sanjeev S. , Shaw Joseph , Evans D. Gareth R. , Kilerci Bedirhan , Pearce Simon P. , Brady Gerard , Dive Caroline , O'Connor James P.B. , Wallace Andrew J. , Rothwell Dominic G. , Edmondson Richard J. , Jayson Gordon C.
Published: April 2023

Kaplan Meier curves.
Supplementary Table S1 from Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry
Authors: Mezghani Nadia , Yao Alexandria , Vasilyeva Daria , Kaplan Nicole , Shackelford Austin , Yoon Angela , Phillipone Elizabeth , Dubey Sunil , Schwartz Gary K. , Taylor Alison M. , Momen-Heravi Fatemeh
Published: April 2023

HNC patient cohort IDs and datasets
Supplementary Figure S8 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Authors: Wils Leon J. , Poell Jos B. , Brink Arjen , Evren Ilkay , Brouns Elisabeth R. , de Visscher Jan G.A.M. , Bloemena Elisabeth , Brakenhoff Ruud H.
Published: April 2023

Overview of the number of CNAs and time to progression for each of the 25 progressors. The top bars show the number of CNAs. The bottom bars show the time to progression in months. CNAs = copy number aberrations.
Supplementary Figure S5 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Authors: Wils Leon J. , Poell Jos B. , Brink Arjen , Evren Ilkay , Brouns Elisabeth R. , de Visscher Jan G.A.M. , Bloemena Elisabeth , Brakenhoff Ruud H.
Published: April 2023

Kaplan-Meier curves for the malignant transformation-free survival of the 89 oral leukoplakia patients in the study stratified by presence of classic or any dysplasia (including differentiated dysplasia). On the y-axis the fraction remaining free of malignant transformation over time is shown. The x-axis shows the time in years. The table below each figure specifies the number of patients at risk at the indicated timepoints for the corresponding groups. Blue lines represent lesions with absence of classic or any dysplasia, while red lines represent lesions with classic or any dysplasia. (A) Kaplan-Meier curves shown for the presence of classic dysplasia for all 89 patients included in the OL-cohort. (B) Kaplan-Meier curves depicted for the presence of any pattern of dysplasia, including differentiated dysplasia, for all 89 patients included in the OL-cohort. Note the tremendous added value of including differentiated dysplasia in the stratification. HR = Hazard ratio.
Supplementary Figure S4 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Authors: Wils Leon J. , Poell Jos B. , Brink Arjen , Evren Ilkay , Brouns Elisabeth R. , de Visscher Jan G.A.M. , Bloemena Elisabeth , Brakenhoff Ruud H.
Published: April 2023

Example staining of differentiated dysplasia. Differentiated dysplasia is characterized by a basal layer of small cells with hyperchromatic or open nuclei with small nucleoli with an abrupt transition to suprabasal large cells with abundant, eosinophilic cytoplasm with differences in eosinophilia, intercellular edema with clearly visible desmosomes, and large, open nuclei with prominent nucleoli.